- In stock, ready to ship
- Inventory on the way
- Ginkgo (Ginkgo biloba)
- European Hazel (Corylus avellana)
- Bilberry (Vaccinium myrtillus)
Protects microcirculation and noble organs
Phyto B.G.H. protects the micro-vessels within critical organs, such as the brain, heart, liver, and kidneys.
European Hazel is central in this complex, it helps oxygenate and profuse the cell.
Diabetes leads to vascular endothelial sclerosis compromising blood flow. The resulting stiffening can lead to hypoxia. The effect is more pronounced within smaller blood vessels because even a slight block of RBC cells can prove troublesome.
Furthermore, dysfunction of vascular structural changes in capillary and basement membranes can contribute to impaired circulation in diabetic foot ulcers.
European Hazel prevents the sclerosis of small vessels of the body including the pulmonary alveoli.
Ginkgo Biloba is a powerful antioxidant, it protects micro-circulation and is a blood vessel opener (vasodilatory). It fights sclerosis and contains anti-aging properties by protecting the mitochondria.
Bilberry complements this complex by also protecting microcirculation. It is specifically indicated for protecting the retina and brain by improving capillary diffusion.
Phyto B.G.H. has the ability to protect small capillary vessels, making it especially beneficial for conditions such as MS, necrosis, diabetic retinopathies.
BL-04 | 2 billion cfu (Bifidobacterium animalis subsp. lactis)
HN019 | 1.8 Billion cfu (Bifidobacterium animalis subsp. lactis)
BB-06 | 5 Billion cfu (Bifidobacterium bifidum)
LA-14 | 2.2 Billion cfu (Lactobacillus acidophilus)
DDS-1 | 5 Billion cfu (Lactobacillus acidophilus)
LL-23 | 2 Billion cfu (Lactococcus lactis)
LPC-37 | 5 Billion cfu (Lactobacillus paracasei)
Lactobacillus plantarum 10 Billion cfu Lp-115
Lactobacillus rhamnosus 2 Billion cfu GG
Bifidobacterium animalis subsp. lactis 5 Billion cfu BLC1
Pediococcus acidilactici 3 Billion cfu UL5
Lactococcus lactis 7 Billion cfu MJC18
Use collapsible tabs for more detailed information that will help customers make a purchasing decision.
Ex: Shipping and return policies, size guides, and other common questions.
Postbiotics are active metabolites produced by commensal gut bacteria. Our HSP Complete 50 Probiotics with Postbiotics contain 3 unique strains capable of producing postbiotics. Bacteriocins are among the many compounds produced by probiotic organisms, and they help to keep the gastrointestinal environment stable and diverse.
Pediococcus acidilactici UL5 is a robust organism capable of withstanding both the human gastric and small intestinal environments. What makes this organism unique is its ability to produce a postbiotic bacteriocin called pediocin PA-1. This postbiotic bacteriocin is an active antimicrobial against pathogenic Listeria species and does not exert detrimental effects on the ileal environment, as demonstrated in a gastrointestinal model.
Similar to Pediococcus acidilactici UL5, Lactococcus lactis MJC18 is another probiotic organism capable of producing a potent postbiotic. The bacteriocin Nisin Z, a postbiotic of Lactococcus lactis MJC18, has antimicrobial activity against many gram positive organisms such as Listeria sp, Staphylococcus sp., Bacillus, and Clostridium. Nisin Z is known for both its bactericidal and bacteriostatic actions against pathogens. When used in combination with methicillin, Nisin Z was shown to improve the efficacy of the antibiotic against methicillin-resistant Staphylococcus Aureus when used topically for 3 hours on porcine skin. More recent studies have discovered that Nisin Z also exerts antiviral properties, especially in combination with antivirals.
Bifidobacterium animalis subsp. lactis BLC1 is an organism used in functional foods and supplements for over a decade. BLC1 has demonstrated some anti-cancer properties in vitro when combined with pro-anthocyanidins in a simulated gastrointestinal model.
HSP Complete 15 is formulated with Lactobacillus acidophilus DDS-1; a strain clinically shown to reduce gastrointestinal discomfort in travel and lactose intolerance. Additionally, this strain has demonstrated an ability to regulate bowel habits and stool consistency. In a double-blind, placebo controlled RCT, Bifidobacterium animalis subsp. lactis HN019 was shown to significantly increase frequency of bowel movements in patients with less than 3 per week.
In another trial with adults 70 years of age and older, HN019 was shown to increase helper T lymphocytes and natural kill cell activity in patients with low immune response.
In a clinical trial comparing the effectiveness of various probiotic strains on immune responses, groups administered Lactobacillus acidophilus La-14 or Bifidobacterium animalis subsp. Lactis BL-04 were shown to significantly increase serum IgG, compared to controls. In a randomized, double-blind placebo controlled trial, Bifidobacterium animalis subsp. Lactis BL-04 was shown to reduce the incidence of respiratory tract infection and viral shedding after being administered during a rhinovirus infection and supplementing with the probiotic strain for an additional 28 days. In another double blind placebo controlled trial with 465 healthy adults, Bifidobacterium animalis subsp. Lactis BL-04 (at a dose of 2 billion CFU) was shown to be more effective than placebo and a multi-strain probiotic (19% reduction vs. 27% reduction) in reducing the incidence of respiratory tract infection and improving immunity.
Chronic medical conditions like obesity and hypertension are modifiable cardiometabolic risk factors highly predictive of hospitalization. Our HSP probiotics have been formulated to address the inflammatory biomarkers, hypercholesterolemia, and elevated BMI typically seen in people with reduced immune function.
In a randomized double-blind placebo controlled trial with 32 overweight and obese women, our HSP strains were shown to be significantly correlated with healthy BMI, weight, fat mass, lean mass, conicity index, protein intake, monounsaturated fat intake, glycated hemoglobin,
TNF-α, and IL6/IL10. The bifidobacteria HSP strains have also demonstrated specific cholesterol absorption properties, leading to decreases in serum total cholesterol and LDL-C.
Lactobacillus rhamnosus GG is among the world’s most heavily studied probiotic strains, and it is an integral part of our HSP Complete formula. With a dose of 2 billion CFU, your digestive, cognitive, and immune health are covered.
Supplementation of rhamnosus GG has been clinically shown to reduce the risk of upper respiratory tract infections, rhinovirus-induced symptoms, acute otitis media, and antibiotic use in populations dealing with viral respiratory infections.
In trials with hospitalized children in both India and Poland, supplementation with rhamnosus GG significantly reduced hospital stay, frequency & duration of diarrhea, and IV therapy requirements. In rotavirus-associated diarrhea, rhamnosus GG supplementation reduced the duration of symptoms, improved gastrointestinal function, and increased IgG.
In patients with Ulcerative Colitis, rhamnosus GG was shown to be as effective as mesalazine in relapse rate after 6 months of supplementation. The probiotic had a better adverse event profile, and was more effective than the drug in promoting “relapse-free time”.
In a randomized placebo controlled trial tracking 6 month old infants to 13 years of age, use of lactobacillus rhamnosus GG resulted in significant risk reduction of ADHD and Asperger’s syndrome.
In two separate clinical trials, rhamnosus GG supplementation starting in the second trimester of pregnancy reduced the severity of maternal allergic disease. During pregnancy and breastfeeding up to the first 2 years of an infant’s life, a study on maternal rhamnosus GG supplementation demonstrated a reduced risk of atopic dermatitis. Extending the benefits to immune and skin health even further, rhamnosus GG supplementation has also been shown to reduce the risk of a child developing atopic dermatitis (eczema), compared to placebo, when taken consistently in the first 7 years of life.
Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236-251. doi:10.1080/19490976.2017.1412908.
Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001;74(6):833-839. doi:10.1093/ajcn/74.6.833.
Paineau D, Carcano D, Leyer G, et al. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 2008;53(1):107-113. doi:10.1111/j.1574-695X.2008.00413.x
Turner et al., (2017) ‘Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomized controlled trial’ Beneficial Microbes, 8(2): 207-215.
West NP et al., (2014), ‘Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy, physically active individuals’, Clinical Nutrition, 33(4):581-7.
Simon M, Pizzorno J, Katzinger J. Modifiable Risk Factors for SARS-CoV-2. Integr Med (Encinitas). 2021;20(5):8-14.
Gomes AC, Hoffmann C, Mota JF. Gut microbiota is associated with adiposity markers and probiotics may impact specific genera. Eur J Nutr. 2020;59(4):1751-1762. doi:10.1007/s00394-019-02034-0
Bordoni A, Amaretti A, Leonardi A, et al. Cholesterol-lowering probiotics: in vitro selection and in vivo testing of bifidobacteria. Appl Microbiol Biotechnol. 2013;97(18):8273-8281. doi:10.1007/s00253-013-5088-2
Davidson, Lisa E. et al. “Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial.” European journal of clinical nutrition 65 (2011): 501 - 507.
Wang B, Hylwka T, Smieja M, Surrette M, Bowdish DME, Loeb M. Probiotics to Prevent Respiratory Infections in Nursing Homes: A Pilot Randomized Controlled Trial. J Am Geriatr Soc. 2018;66(7):1346-1352. doi:10.1111/jgs.15396.
Liu, S., Hu, P., Du, X. et al. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: A Meta-analysis of Randomized, Placebo-controlled Trials . Indian Pediatr 50, 377–381 (2013)
Basu S, Paul DK, Ganguly S, Chatterjee M, Chandra PK. Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol. 2009 Mar;43(3):208-13. doi: 10.1097/MCG.0b013e31815a5780. PMID: 18813028.
Czerwionka-Szaflarska M, Murawska S, Swincow G. Evaluation of influence of oral treatment with probiotic and/or oral rehydration solution in the course of acute diarrhea in children. Gastroenterology Review/Przegląd Gastroenterologiczny. 2009;4(3):166-172.
Sindhu KN, Sowmyanarayanan TV, Paul A, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2014;58(8):1107-1115. doi:10.1093/cid/ciu065.
Pieścik-Lech, Małgorzata et al. “Lactobacillus GG (LGG) and smectite versus LGG alone for acute gastroenteritis: a double-blind, randomized controlled trial.” European Journal of Pediatrics 172 (2012): 247 - 253.
Zocco, M A et al. “Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.” Alimentary pharmacology & therapeutics vol. 23,11 (2006): 1567-74. doi:10.1111/j.1365-2036.2006.02927.x.
Pärtty A, Kalliomäki M, Wacklin P, Salminen S, Isolauri E. A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood: a randomized trial. Pediatr Res. 2015 Jun;77(6):823-8. doi: 10.1038/pr.2015.51. Epub 2015 Mar 11. PMID: 25760553.
Ou CY, Kuo HC, Wang L, et al. Prenatal and postnatal probiotics reduces maternal but not childhood allergic diseases: a randomized, double-blind, placebo-controlled trial. Clin Exp Allergy. 2012;42(9):1386-1396. doi:10.1111/j.1365-2222.2012.04037.x
Rautava S, Kalliomäki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002;109(1):119-121. doi:10.1067/mai.2002.120273
Kalliomäki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119(4):1019-1021. doi:10.1016/j.jaci.2006.12.608